About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

New Drugs With RNA Interference Therapy For Hepatitis B

by Julia Samuel on November 27, 2017 at 2:52 PM
Font : A-A+

New Drugs With RNA Interference Therapy For Hepatitis B

A new treatment now in human trials for chronic hepatitis B virus (HBV) infection is tested at the Southwest National Primate Research Center (SNPRC).

Testing at SNPRC provided proof this novel therapeutic approach and drug delivery mechanism would be safe and effective, as recently published in the international journal Science Translational Medicine.

Advertisement


The World Health Organization characterizes hepatitis B as a major global health problem. An estimated 250 to 400 million people are chronically infected with the virus. More than 800,000 people a year die from complications of cirrhosis of the liver and liver cancer.

A vaccine that is 95% effective in preventing hepatitis B infections has been available since 1982, but there is currently no cure for the millions already chronically infected.
Advertisement

The novel therapy by Arrowhead Pharmaceuticals uses a mechanism called RNA interference to reduce the surface antigens created by chronic HBV infections. Surface antigens (called HBsAg) are small molecules involved in virus entry into liver cells. In chronic infection, they may prevent the immune response from clearing the virus.

For example, a high level of HBsAg can lead to a greater risk of long-term, chronic infection with hepatitis B and life-threatening complications like cirrhosis and liver cancer. In this setting, reducing HBsAg by RNA interference will have beneficial effects.

Much of the groundbreaking work lies in the technology Arrowhead developed for delivering this small interfering RNA precisely to the liver. Experiments involving chimpanzees at the SNPRC from 2013-2015 provided the proof that this technology works and is safe for humans, laying the groundwork for the patient clinical trials that have followed. Trials of targeted HBV intervention in non-human primates showed the experimental drug was safe and effective enough to be tested in people.

The Director of the SNPRC, Robert Lanford, Ph.D., explained this novel treatment -- in combination with conventional HBV therapy -- could empower the immune system to kill the HBV-infected cells and potentially cure people of the disease.

"We now have a drug that can knock down hepatitis B surface antigen and determine whether or not we can actually cure people with that," Dr. Lanford said.

The drug is delivered by subcutaneous (under the skin) injection. Scientists designed a molecule that delivers the medicine directly to the liver where it binds to a receptor. Then, another molecule that's derived from bee venom, helps break through membranes in the liver cells to deliver the medicine directly into the cytoplasm of the cells where it takes effect. The siRNA interferes with the expression of the HBV messenger RNA that produces the surface antigen.

"The idea is if you could knock the levels of surface antigens down far enough, the immune system would kick back in," Dr. Lanford said. "This technology is pretty specific for the liver right now, but there are a lot of problems in the liver that you can fix with this besides hepatitis B."

This kind of targeted therapy may someday be used to develop drugs for other chronic liver conditions like a genetic disorder called Alpha-1 antitrypsin deficiency, caused by mutated inherited genes, which can cause cancer.

Although the SNPRC no longer uses chimpanzees for biomedical research, studies conducted with these non-human primates over decades continue to yield significant scientific information that will advance human health.

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
Black Tea Protects against Blood Pressure and Heart Diseases
Green Mediterranean Diet may Help Repair Age-Related Brain Damages
Cervical Cancer Awareness Month 2022
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Hepatitis A Hepatitis B Hepatitis B Virus Reiki and Pranic Healing Silent Killer Diseases Liver Drugs Banned in India Aplastic Anemia HBV Screening 

Recommended Reading
Hepatitis B
Hepatitis B is inflammation of the liver due to infection with the hepatitis B virus....
Neonatal Hepatitis
Neonatal hepatitis is an inflammation of the liver that usually occurs in early infancy and is ......
HBV Screening
Tests used for screening hepatitis B are estimation of hepatitis B surface antigen (HBsAg), ......
Tests for Hepatitis
Hepatitis is an inflammation of the liver. Hepatitis virus panel is a series of blood tests to ......
Aplastic Anemia
Aplastic anemia (AA) is a term that refers to a condition where the body fails to produce enough blo...
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Drugs Banned in India
Several drugs are either banned or withdrawn after introduction in the market....
Hepatitis A
Hepatitis A is the most benign of the hepatitis viruses and usually has no long term side effects. H...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
open close
ASK A DOCTOR ONLINE
I have read and I do accept terms of use - Telemedicine

Advantage Medindia: FREE subscription for 'Personalised Health & Wellness website with consultation' (Value Rs.300/-)